8-K: Leap Therapeutics Completes Enrollment in Key Colorectal Cancer Study

Leap Therapeutics has completed enrollment of 188 patients in Part B of the DeFianCe study, evaluating DKN-01 for advanced colorectal cancer.

Summary

• Leap Therapeutics has finished enrolling 188 patients in the randomized controlled Part B of the DeFianCe study.
• The study is evaluating DKN-01, an anti-DKK1 antibody, in combination with standard treatments for advanced colorectal cancer.
• Part B of the study expanded from 130 to 188 patients and is focused on patients who have already received one prior systemic therapy.
• The primary endpoint of the study is progression-free survival (PFS), with an additional primary endpoint for the subpopulation of patients with left-sided colorectal cancer.
• Secondary objectives include objective response rate, duration of response, and overall survival.
• Initial data from Part B, including the left-sided CRC subpopulation, is expected in mid-2025.

Sentiment

Score: 7

Explanation: The document is positive due to the completion of enrollment in a key clinical trial, but it also includes standard risk disclosures, resulting in a moderately positive sentiment.

Positives

• The completion of enrollment in Part B of the DeFianCe study is a significant milestone.
• The study has expanded from 130 to 188 patients, indicating strong interest in the trial.
• Encouraging data from Part A of the study showed clinically meaningful response rates and durable tumor reductions.
• DKN-01 has demonstrated a favorable safety profile in advanced CRC patients.

Risks

• The company's ability to successfully execute its clinical trials and the timing of enrollment in and cost of such clinical trials could impact results.
• The results of clinical trials may not be as positive as preliminary data suggests.
• The company may not be able to successfully enter into new strategic partnerships for DKN-01 or any of its other programs.
• There is no guarantee that any Leap products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies.
• The company is exposed to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of its traded securities.
• Global conflict or supply chain related issues may delay or adversely affect clinical trials, laboratory operations, manufacturing campaigns, and other studies.

Future Outlook

The company anticipates sharing initial data from Part B of the DeFianCe study, including the subpopulation of patients with left-sided CRC, in mid-2025.

Management Comments

• Cynthia Sirard, M.D., Chief Medical Officer of Leap, stated that the completion of enrollment in Part B of the DeFianCe study marks a significant achievement and highlights the enthusiasm in the potential of DKN-01 from both patients and healthcare providers.
• The encouraging data from Part A of the study provides a strong foundation to the expanded Part B of the study.

Industry Context

The announcement is relevant to the oncology and biotechnology industries, specifically in the development of new treatments for advanced colorectal cancer. The completion of enrollment is a key step in the clinical development process.

Comparison to Industry Standards

• The DeFianCe study is a Phase 2 trial, which is a common stage for evaluating the efficacy of new cancer treatments.
• The use of progression-free survival (PFS) as a primary endpoint is standard in oncology clinical trials.
• The study's focus on a specific subpopulation (left-sided CRC) is becoming more common as personalized medicine gains traction.
• Other companies such as Amgen with Vectibix and Eli Lilly with Cyramza are also developing treatments for colorectal cancer, making this a competitive space.

Stakeholder Impact

• Shareholders may view the completion of enrollment positively.
• Patients with advanced colorectal cancer may benefit from the potential new treatment.
• Healthcare providers will be interested in the results of the study.
• Employees of Leap Therapeutics are likely to be encouraged by the progress of the clinical trial.

Next Steps

• The company will continue to monitor patients in the DeFianCe study.
• The company will analyze the data from Part B of the study.
• The company will release initial data from Part B of the study in mid-2025.

Key Dates

Keywords

DKN-01, colorectal cancer, clinical trial, DeFianCe study, oncology, biotechnology, progression-free survival, LPTX